Breast-Gynecological and Immunology International Cancer Conference

Starts:  Jan 19, 2017 00:00 (EET)
Ends:  Jan 20, 2017 00:00 (EET)

Presented by the Breast-Gynecological International Cancer Society in collaboration with the Society for Immunotherapy of Cancer

The Ninth Breast-Gynecological and Immunology International Cancer Conference (BGICC) is the only conference specialized in breast and gynecological cancers in Africa and the Middle East. The conference strives to provide a platform for the exchange of experience and to outline the status of problems relating to breast and gynecological cancers, with discussion of the most recent international trends and initiatives for treatment.

This year the conference also includes a plenary session on immuno-oncology, followed by a recommendation session during which a panel of experts in the field will vote on and discuss recommendations for patient selection and immunotherapy treatment for a variety of cancer types.

BGIICC is presented by the Breast-Gynecological International Cancer Society (BGICS), which was established to advance the art, science and practice of medicine for the treatment of cancer by working collaboratively with other cancer organizations via arranging scientific conferences and professional exchanges; sharing knowledge and course endeavors; disseminating relevant ideas and research to the cancer community; revealing the causes of breast and gynecological cancers and the mechanisms of carcinogenesis; and developing scientific strategies for the highest possible standard for cancer control.

Immunotherapy Tsunami Session Speakers and Topics (January 19, 2017)

2:30 – 2:50 p.m. Why Immunotherapy is a Real Breakthrough (Mechanisms and Overview)
Hamdy Abdel Azim, MD, MSc – Cairo University
Challenges in Immunotherapy
2:50 – 3:05 p.m. To Test or Not to Test PD1/PDL1:  Is it Mandatory; Is it Site Dependent?
Neal E. Ready, MD, PhD – Duke Cancer Institute
3:05 – 3:20 p.m. Assessment of Response and Definition of Pseudoprogression
Leisha A. Emens, MD, Phd – Johns Hopkins University
3:20 – 3:35 p.m. What is Beyond Progression After Immunotherapy?
J. P. de Boer, MD – Netherlands Cancer Institute
NSCLC: The History Started to Change
3:35 – 3:55 p.m. First-Line Immunotherapy
David P. Carbone, MD, PhD – Vanderbilt University Cancer Center
3:55 – 4:15 p.m. Second Line and Beyond
Neal E. Ready, MD, PhD – Duke Cancer Institute
4:15 – 4:30 p.m. EGFR and ALK Mutation Population: What is the Best Scenario?
Federico Cappuzzo, MD, PhD – Ospedale Civile
4:30 – 4:50 p.m. Conclusion: Can We Establish an Algorithm for Management of NSCLC?
First Line: Yasser S. Abd El Kader, MD, MSc – Cairo University
Second Line: Rabab M. Gaafar, MD, MSc – National Cancer Institute, Cairo

ASCO-SITC-BGICS Recommendations in Immuno-Oncology Panel (January 20, 2017)

3:45 – 4:45 p.m. Moderators                                                                                             
Leisha A. Emens, MD, PhD – Johns Hopkins University
Mohsen Mokhtar, MD – Cairo University

#Collaboration #2017 #Oncologist #Researcher


Fairmont Towers Hotel
El-Orouba, Qism El-Nozha
Cairo Governorate 11736